Skip to main content

A blood based biomarker identifying early Alzheimer Disease's pathology

Project description

Diagnostic tool to detect emerging Alzheimer's disease

Alzheimer's disease (AD) is not curable at the final stages, but early detection and treatment could provide significant therapeutic and societal benefits. Treatment started at the early stages could either slow down or even cure AD, dramatically reducing healthcare costs. Norwegian company Pre Diagnostics is working to create a diagnostic tool to identify patients at the earliest stages before AD is evident. The accurate and cost-effective blood biomarker detection tool will directly analyse patients’ brain metabolism and detect reduced clearance of beta-amyloid, which is the earliest signal in AD pathology. The EU-funded VERDAD project will provide support for the final regulatory steps in the development of the novel tool and prepare it for the market.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-2

Coordinator

PRE DIAGNOSTICS AS
Net EU contribution
€ 2 355 791,00
Address
Skogfaret 25 B
0382 Oslo
Norway

See on map

Region
Norge Oslo og Viken Oslo
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 1 009 625,25